|Bid||15.90 x 900|
|Ask||24.93 x 1400|
|Day's Range||18.56 - 19.45|
|52 Week Range||16.41 - 29.02|
|Beta (5Y Monthly)||1.58|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 15, 2023 - Feb 20, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||44.27|
Subscribe to Yahoo Finance Plus to view Fair Value for INSM
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present at the Nasdaq 47th Investor Conference in London on Wednesday, December 7 at 8:30 a.m. EST/1:30 p.m. GMT.
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 18 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
One thing investors are not lacking for after 2022’s market rout: beaten-down stocks going for cheap compared to levels seen at the start of the year. The problem is how can investors sift through the stock debris to pick out the names which will dust themselves down and push ahead again? As with anything, there are multiple ways to run a stock through the litmus test, but one tried-and-true method is to watch out for the moves the insiders make. These corporate officers know the inner workings